Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Opus Genetics, Inc. (IRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IRD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.5
1 Year Target Price $10.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.35% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.67M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 3 | Beta 0.24 | 52 Weeks Range 0.65 - 1.56 | Updated Date 07/3/2025 |
52 Weeks Range 0.65 - 1.56 | Updated Date 07/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -207.11% |
Management Effectiveness
Return on Assets (TTM) -38.95% | Return on Equity (TTM) -64.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -962644 | Price to Sales(TTM) 4.26 |
Enterprise Value -962644 | Price to Sales(TTM) 4.26 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA -2.55 | Shares Outstanding 31568500 | Shares Floating 27724682 |
Shares Outstanding 31568500 | Shares Floating 27724682 | ||
Percent Insiders 16.15 | Percent Institutions 16.63 |
Upturn AI SWOT
Opus Genetics, Inc.
Company Overview
History and Background
Opus Genetics, Inc. is a gene therapy company focused on developing treatments for inherited retinal diseases. Founded in 2020, it emerged from the Foundation Fighting Blindness's venture arm, the RD Fund. Its focus is on rare subtypes of inherited retinal disease where existing therapies are limited.
Core Business Areas
- Gene Therapy Development: Focuses on developing adeno-associated virus (AAV)-based gene therapies to address specific genetic mutations causing inherited retinal diseases.
- Rare Disease Focus: Concentrates on developing treatments for rare and underserved inherited retinal diseases.
- Preclinical and Clinical Research: Conducts research and clinical trials to evaluate the safety and efficacy of its gene therapy candidates.
Leadership and Structure
The leadership team consists of experienced biotech executives and scientists specializing in gene therapy and ophthalmology. Tom Raffin serves as acting CEO and Board member. The organizational structure likely involves research, development, clinical operations, and regulatory affairs departments.
Top Products and Market Share
Key Offerings
- OPH1-001: A gene therapy candidate targeting mutations in the NMNAT1 gene, which causes Leber congenital amaurosis (LCA). Market share data is not publicly available as it is in clinical development. Potential competitors include companies developing gene therapies for LCA, such as MeiraGTx and Spark Therapeutics (now part of Roche).
- Irenexocal: Irenexocal is a therapeutic developed by Opus Genetics to treat retinal diseases. Market share data is not publicly available as it is still under clinical trials, competitors are also in the process of treating this disease with gene therapies
Market Dynamics
Industry Overview
The gene therapy market for inherited retinal diseases is growing rapidly, driven by advances in gene delivery technologies and a better understanding of the genetic causes of these conditions. The FDA has approved a few gene therapies for inherited retinal diseases, paving the way for further development and commercialization.
Positioning
Opus Genetics is positioned as a company focused on addressing unmet needs in rare inherited retinal diseases, leveraging its relationship with the Foundation Fighting Blindness to access expertise and funding.
Total Addressable Market (TAM)
The total addressable market for gene therapies targeting inherited retinal diseases is estimated to be billions of dollars, with a significant portion attributed to rare subtypes. Opus Genetics is focused on capturing a share of this market by developing therapies for underserved patient populations.
Upturn SWOT Analysis
Strengths
- Focus on rare and underserved inherited retinal diseases
- Strong relationship with the Foundation Fighting Blindness
- Experienced leadership team in gene therapy and ophthalmology
- Proprietary AAV-based gene therapy platform
Weaknesses
- Early stage of development with limited clinical data
- Dependence on funding and partnerships
- High regulatory hurdles for gene therapies
- Limited commercial infrastructure
Opportunities
- Expanding pipeline of gene therapy candidates
- Partnerships with pharmaceutical companies
- Accelerated regulatory pathways for rare disease treatments
- Increasing awareness and acceptance of gene therapy
Threats
- Competition from established gene therapy companies
- Adverse clinical trial results
- Manufacturing challenges and high costs
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- SPK (Roche)
- ASG (MeiraGTx)
- EDGN
Competitive Landscape
Opus Genetics faces competition from larger, more established gene therapy companies. Its advantage lies in its focus on rare diseases and its collaboration with the Foundation Fighting Blindness.
Growth Trajectory and Initiatives
Historical Growth: Limited data available due to the early stage of the company.
Future Projections: Future growth will depend on the success of its clinical trials and regulatory approvals. Analyst estimates are not readily available.
Recent Initiatives: Focus on advancing OPH1-001 into later-stage clinical trials and expanding its pipeline with new gene therapy candidates.
Summary
Opus Genetics is a young gene therapy company focusing on rare inherited retinal diseases. Their connection to Foundation Fighting Blindness gives them advantages but still need to complete several clinical trials and approval. The company shows good growth potential if clinical trials and financial backing continues to come in. As a start up, it is vital for them to compete with those with bigger financial backing, and more established gene therapy companies. The changing regulatory landscape can affect its projected path.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Opus Genetics Website
- Foundation Fighting Blindness Website
- SEC Filings of Publicly Traded Competitors
- Industry Reports on Gene Therapy
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is estimated based on industry reports and competitor analysis. Financial data is limited due to the company's private status.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opus Genetics, Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2005-05-23 | CEO & Director Mr. George Magrath M.B.A., M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://opusgtx.com |
Full time employees 18 | Website https://opusgtx.com | ||
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.